Alex Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 2.76 Cr
as on 16-11-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.11 Cr
as on 16-11-2024
- Revenue 47.46%
(FY 2023)
- Profit 66.33%
(FY 2023)
- Ebitda 280.03%
(FY 2023)
- Net Worth 51.93%
(FY 2023)
- Total Assets -2.63%
(FY 2023)
About Alex Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.76 Cr.
The company currently has active open charges totaling ₹18.11 Cr.
Kishorkumar Kachhadia and Vipulbhai Antala serve as directors at the Company.
- CIN/LLPIN
U24110GJ2021PTC120066
- Company No.
120066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alex Pharmachem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishorkumar Kachhadia  | Director | 08-Feb-2021 | Current |
| Vipulbhai Antala | Director | 08-Feb-2021 | Current |
Financial Performance of Alex Pharmachem.
Alex Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.46% increase. The company also saw a substantial improvement in profitability, with a 66.33% increase in profit. The company's net worth Soared by an impressive increase of 51.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alex Pharmachem?
In 2023, Alex Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fragment Care Private LimitedActive 3 years 6 monthsKishorkumar Kachhadia and Vipulbhai Antala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 03 Jun 2022 | ₹9.00 Cr | Open |
Axis Bank Limited Creation Date: 27 May 2022 | ₹9.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Dec 2021 | ₹1.10 M | Open |
How Many Employees Work at Alex Pharmachem?
Alex Pharmachem has a workforce of 44 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alex Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alex Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
